Companies → EIDP, Inc.
Save to list
Remove

EIDP, Inc.

United States, Indiana, Indianapolis
Description
EIDP, Inc. engages in developing and supplying commercial seed and crop protection products for the agriculture industry in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through two segments: Seed and Crop Protection. The Seed segment offers corn, soybean, and other oil seeds; trait technologies that enhance resistance to weather, disease, insects, and herbicides, which is used to control weeds; and digital solutions that assist farmer decision-making, as well as develops and supplies germplasm and traits that produce yield for farms. The Crop Protection segment offers insect and nematode management, disease management, weed control, nitrogen management, and biological products to protect against weeds, insects and other pests, and disease for the input agricultural industry. It markets and distributes its products through agency model, regional brands, and retail brands, as well as third parties. EIDP, Inc. was formerly known as E. I. du Pont de Nemours and Company and changed its name to EIDP, Inc. in January 2023. The company was founded in 1802 and is based in Indianapolis, Indiana. EIDP, Inc. operates as a subsidiary of Corteva, Inc.
Address:

9330 Zionsville Rd Indianapolis

IN

46268-1053 United States

Website:
Revenue
Recent news:

Deere, Caterpillar and 10 Other Stocks for an AI-Infused Blue Collar Renaissance

Artificial intelligence is the angel and demon fueling most stock trades these days, whether boosting companies tied to hyperscalers’ hyperspending on AI data centers or tanking software companies’ shares on fears of permanent irrelevance. “Justifiable attention has been paid to [AI’s] impact on the white-collar workforce,” wrote Oppenheimer analysts led by Colin Rusch in a Thursday report. “As such, we see a multi-year supportive backdrop across our Industrial Innovation coverage...

Source: Barrons.com Mar 12, 2026

Is Corteva Stock Underperforming the Nasdaq?

While Corteva has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Source: Barchart Mar 10, 2026

Is Corteva (CTVA) Fairly Priced After Strong Multi‑Year Share Price Gains

If you have been wondering whether Corteva's current share price lines up with its underlying worth, you are not alone. This article is built to help you assess that question clearly. Corteva's share price recently closed at US$78.30, with returns of 7.9% over the last 30 days, 15.6% year to date, 31.3% over 1 year, 38.1% over 3 years and 76.6% over 5 years. This may signal that the market's view of its risk and opportunity has shifted over time. Recent coverage around Corteva has focused on...

Source: Simply Wall St. Mar 10, 2026

Corteva Biofungicide Push And Business Split Reshape Long Term Story

Corteva (NYSE:CTVA) is partnering with Ascribe Bio to develop seed-applied biofungicide technology aimed at more targeted disease control in crops. The company has also announced an upcoming Investor Day, where it plans to outline the separation of its seed genetics and crop protection businesses. These moves highlight Corteva's focus on reshaping its portfolio and product pipeline in agricultural inputs. Corteva, trading at $78.3, sits in a stronger spot than a year ago, with the share...

Source: Simply Wall St. Mar 10, 2026

AVO's International Farming Bounces Back: Can It Stay Consistent?

Mission Produce's international farming rebounds with stronger yields and higher volumes after past weather disruptions.

Source: Zacks Mar 9, 2026

How The Corteva (CTVA) Investment Story Is Shifting As Analysts Rework Targets

Corteva’s latest fair value estimate has nudged higher, moving from US$82.05 to US$82.76 per share, putting the modeled target firmly in the low US$80s. That shift comes as Street research stays divided, with some firms lifting targets into a similar range while others issue downgrades and question the current risk reward. Read on to see how you can track these changing targets and make sense of the evolving Corteva story for yourself. Analyst Price Targets don't always capture the full...

Source: Simply Wall St. Feb 26, 2026

NYSE - Delayed Quote - USD
CTA-PB
68.00 -0.40 (-0.58%)
At close March 20 20:00 UTC
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/19/2026
Market Cap: 59.36 B
Enterprise Value: N/A
Trailing P/E: N/A
Forward P/E: N/A
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 3.41
Price/Book (mrq): N/A
Enterprise Value/Revenue: N/A
Enterprise Value/EBITDA: N/A
Financial Highlights
Profitability and Income Statement
Profit Margin: 6.34%
Return on Assets (ttm): 3.88%
Return on Equity (ttm): 4.99%
Revenue (ttm): 17.40 B
Net Income Avi to Common (ttm): 1.19 B
Diluted EPS (ttm): N/A
Balance Sheet and Cash Flow
Total Cash (mrq): 4.53 B
Total Debt/Equity (mrq): 12.34%
Levered Free Cash Flow (ttm): 3.06 B
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.